866405-64-3 | Dorsomorphin (Compound C / HY-13418A)

Chemical type

• Small-molecule inhibitor
• Pyrazolopyrimidine derivative

^[1]

• Small-molecule BMP signaling inhibitor (Type I BMP receptor inhibitor)

^[2]

Key properties

• AMP-activated protein kinase (AMPK) inhibitor

^[1]

• Highly selective inhibitor of BMP type I receptors (ALK2, ALK3, ALK6)
• Does not inhibit BMPR2, allowing MAPK signaling to remain active
• Blocks Smad1/5/8 phosphorylation, suppressing mesoderm and endoderm induction
• Promotes ectodermal/neuroectodermal bias

^[2]

• Pharmacological tool to inhibit AMPK pathway in research
• Used in vitro to reverse protective effects of ANKRD1 knockdown

^[1]

• Direct chemical induction of neuroectodermal cells from human fibroblasts
• Core component of the DSM + TSA cocktail for transdifferentiation

^[2]

Classification by use

• Biochemical pathway inhibitors (AMPK-specific)
• Research chemicals for mechanistic studies

^[1]

• Small molecules for cellular reprogramming
• BMP signaling inhibitors
• Neuroectodermal induction agents

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] ANKRD1 knockdown attenuates doxorubicin-induced dilated cardiomyopathy by regulating mitochondrial dysfunction and oxidative stress through activation of the AMPK/AKT/mTOR pathway, Electronic Journal of Biotechnology, Volume 79, January 2026, 100696
2. [Cite:2] Full small molecule conversion of human fibroblasts to neuroectodermal cells via a cocktail of Dorsomorphin and Trichostatin A, Regenerative Therapy, Volume 15, December 2020, Pages 44-52